Zobrazeno 1 - 10
of 11 190
pro vyhledávání: ''
Autor:
Daniel Moj, Nicola Ammer, Babette Aicher, Jan-Georg Wojtyniak, Thorsten Lehr, Michael Teifel, Herbert Sindermann, Hannah Britz, Nina Hanke
Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors. The aim of this study was to establish a physi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c5e9a18956370d7aca5ee1061fd910
Autor:
Daniel M. Berney, Jonathan Shamash, T. Oliver, Anju Sahdev, S. J. Harland, Andrew Gogbashian, Constantine Alifrangis, Gordon J. S. Rustin, Samita Agarwal, Marina Milic, Sarah Duncan, Sara Stoneham, Shafi Chowdhury, Anand Sharma, Michelle Lockley, Peter Wilson
Publikováno v:
European Journal of Cancer. 164:105-113
Background Radiotherapy and cisplatin-based combination chemotherapy are accepted standard-of-care treatments for metastatic seminoma with excellent survival outcomes but with established short- and long-term morbidity. Carboplatin monotherapy may be
Autor:
Francesca Ragusa, Alessandro Antonelli, Gilda Varricchi, Poupak Fallahi, Maria Rosaria Galdiero, Giusy Elia, Salvatore Benvenga, Silvia Martina Ferrari, Sabrina Rosaria Paparo
Publikováno v:
Seminars in Cancer Biology. 79:180-196
Thyroid cancer (TC) is the eighth most frequently diagnosed cancer worldwide with a rising incidence in the past 20 years. Surgery is the primary strategy of therapy for patients with medullary TC (MTC) and differentiated TC (DTC). In DTC patients, r
Autor:
Yunfei Wang, Yin Wan, Nicholas J. Vogelzang, Yiqiong Xie, Nicholas J. Robert, Alisha M. Monnette, Nizar M. Tannir
Publikováno v:
Clinical Genitourinary Cancer. 19:531-539
Introduction Few studies have evaluated real-world effectiveness of lenvatinib (Len)/everolimus (Eve) for advanced/metastatic renal cell carcinoma (a/mRCC). This study evaluated patient profiles and clinical outcomes of second- and subsequent-line (
Autor:
Anthony M. Joshua, Louise Emmett, Christopher Rofe, Jesse A Ende, Andrew Nguyen, Arnavaz Danesh, Edmond M. Kwan, Lyn Chan, Andrew O. Yam, Shikha Sharma, Megan Crumbaker, Joanne Keane, Sarennya Pathmanandavel, Kamonwan Kongrak, Bao Ho, Peter Eu, Trevor J. Pugh, Arun Azad
Publikováno v:
European Urology Oncology. 4:963-970
Background Trials of lutetium prostate specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC) have demonstrated good safety and efficacy, but combination strategies may improve outcomes. Idronoxil is a sy
Autor:
Justin Buthorn, Noam Shomron, Fleur Cohen, Jean-François Emile, Roei D Mazor, Ofer Shpilberg, Omar Abdel-Wahab, Zahir Amoura, Eli L. Diamond, Ran Weissman, Benjamin H. Durham, Julien Haroche, Oshrat Hershkovitz-Rokah
Publikováno v:
Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, ⟨10.1038/s41375-021-01472-2⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, ⟨10.1038/s41375-021-01472-2⟩
Erdheim–Chester disease (ECD) is characterized by excessive production and accumulation of histiocytes within multiple tissues and organs. ECD patients harbor recurrent mutations of genes associated with the RAS/RAF/MEK/ERK signaling pathway, parti
Autor:
Stefano Mangiola, Jeremy Grummet, Michael Kerger, Paul Ruljancich, Ryan Stuchbery, David Clarke, Justin S. Peters, Andrew Ryan, Niall M. Corcoran, Phillip Parente, Nicholas Howard, Christopher M. Hovens, Natalie Kurganovs, Sam Norden, Anthony J. Costello, Anne Ngyuen, Corrina A Grima, Patrick McCoy, Geoff Macintyre, Philip Dundee, Marek Cmero, Ken Chow
Publikováno v:
JCO Precision Oncology
PURPOSE Androgen receptor (AR) signaling is important in prostate cancer progression, and therapies that target this pathway have been the mainstay of treatment for advanced disease for over 70 years. Tumors eventually progress despite castration thr
Publikováno v:
Clinical Lung Cancer. 22:e921-e924
Background Pembrolizumab monotherapy or immune checkpoint inhibitor with platinum and pemetrexed combination chemotherapy are the standard therapies for patients with nonsquamous non–small-cell lung cancer (NSCLC) with programmed cell death ligand-
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:734-740
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy arising from the aberrant transformation of plasmacytoid dendritic cells (pDCs) and involving skin, bone marrow, lymph nodes, and central nervous system. Characteri
Autor:
Guido von Figura, Patrick Wenzel
Publikováno v:
TumorDiagnostik & Therapie. 42:655-661
Ductal pancreatic carcinoma is expected to become one of the most common malignant diseases worldwide in the coming decades. However, the prognosis of the disease remains very poor and has improved only slightly over the last decade. The 5-year survi